Brookings Health System | |
300 22nd Ave, Brookings, South Dakota 57006 | |
(605) 696-9000 | |
Name | Brookings Health System |
---|---|
Type | Acute Care Hospital |
Location | 300 22nd Ave, Brookings, South Dakota |
Ownership | Government - Local |
Emergency Services | Yes |
Medicare ID (CCN) | 430008 |
NPI Number | 1003060146 |
Organization Name | BROOKINGS HEALTH SYSTEM |
Address | 300 22nd Ave, Brookings, SD 57006 |
Hospital Type | General Acute Care Hospital |
Phone Number | 605-696-9000 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
A recently released Drug Diagnosis Coding database from RJ Health Systems provides accurate FDA-approved and Compendia-listed off-label uses for therapeutic classes such as Oncology, Anti-Emetics, Erythropoietin Stimulating Agents and Multiple Sclerosis Agents. The
By peering at the brains of study subjects prompted to suppress negative emotions, scientists have gained new insights into how emotional regulation influences negative feelings and memories. The researchers hope the findings will lead to new methods to combat depression.
Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.
› Verified 6 days ago
NPI Number | 1275515579 |
Organization Name | CITY OF BROOKINGS |
Doing Business As | BROOKINGS HEALTH SYSTEM |
Address | 300 22nd Ave, Brookings, SD 57006 |
Hospital Type | General Acute Care Hospital |
Phone Number | 605-696-9000 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
A recently released Drug Diagnosis Coding database from RJ Health Systems provides accurate FDA-approved and Compendia-listed off-label uses for therapeutic classes such as Oncology, Anti-Emetics, Erythropoietin Stimulating Agents and Multiple Sclerosis Agents. The
By peering at the brains of study subjects prompted to suppress negative emotions, scientists have gained new insights into how emotional regulation influences negative feelings and memories. The researchers hope the findings will lead to new methods to combat depression.
Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.
› Verified 6 days ago
NPI Number | 1700962834 |
Organization Name | CITY OF BROOKINGS |
Doing Business As | BROOKINGS HEALTH SYSTEM |
Address | 300 22nd Ave, Brookings, SD 57006 |
Hospital Type | General Acute Care Hospital |
Phone Number | 605-696-9000 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
A recently released Drug Diagnosis Coding database from RJ Health Systems provides accurate FDA-approved and Compendia-listed off-label uses for therapeutic classes such as Oncology, Anti-Emetics, Erythropoietin Stimulating Agents and Multiple Sclerosis Agents. The
By peering at the brains of study subjects prompted to suppress negative emotions, scientists have gained new insights into how emotional regulation influences negative feelings and memories. The researchers hope the findings will lead to new methods to combat depression.
Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.
› Verified 6 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
A recently released Drug Diagnosis Coding database from RJ Health Systems provides accurate FDA-approved and Compendia-listed off-label uses for therapeutic classes such as Oncology, Anti-Emetics, Erythropoietin Stimulating Agents and Multiple Sclerosis Agents. The
By peering at the brains of study subjects prompted to suppress negative emotions, scientists have gained new insights into how emotional regulation influences negative feelings and memories. The researchers hope the findings will lead to new methods to combat depression.
Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.
› Verified 6 days ago
Brookings Health System Acute Care Hospital Location: 300 22nd Ave, Brookings, South Dakota 57006 Phone: (605) 696-9000 |